AI drug discovery firm inks investment and collaboration deal with NVIDIA
Genesis to work with NVIDIA to optimize its neural network architectures around 3D geometric data of proteins and drug-like molecules.
Artificial intelligence-powered drug discovery company Genesis Therapeutics has announced a new equity investment and strategic collaboration with tech giant 英伟达 , aiming to push forward advancements in its AI platform. The equity contribution comes from NVentures, the venture capital division of NVIDIA, which also took part in the last year’s oversubscribed $200 million Series B round and brings the total raised by the company to more than $300 million to date.
My take on this: Genesis, a Burlingame, CA-based company, uses advanced AI to combat hard-to-treat proteins often seen as “undruggable.” Through its GEMS AI platform, Genesis combines predictive and generative AI to speed up small molecule drug development. This platform integrates cutting-edge AI, including language and diffusion models, with machine learning simulations, making it a powerful tool for creating and refining drug molecules with high precision.
“Addressing previously undruggable targets to create new medicines requires pioneering algorithms for drug discovery and fundamental infrastructure innovation,” said Dr Evan Feinberg , founder and CEO of Genesis. “Working with NVIDIA, we will further the capabilities of our field-leading physical AI platform for structure-driven drug design.”
A significant aspect of the GEMS platform is its ability to understand and interpret the three-dimensional structure and interactions between proteins and potential drug molecules. Using a graph-based approach to represent protein-ligand complexes, the platform makes accurate predictions based solely on 3D structural information. This understanding is crucial for designing effective drugs, especially for targets considered difficult or impossible to address using traditional methods. GEMS also features a molecular simulation component that captures 3D binding dynamics, enhancing its ability to generate innovative molecules that can be explored in specific chemical spaces tailored to each drug development program.
Explore the groundbreaking collaboration between Genesis and NVIDIA right HERE .
Thanks for reading! If you’ve enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!
Assistant Professor at Georgetown University School of Medicine
1 周"The collaboration with NVIDIA aims to bring new computational efficiencies to Genesis’s platform, particularly through the optimization of neural network architectures critical for drug discovery. One of the main areas of focus will be refining equivariant neural networks, which are essential for managing 3D geometric data, such as the structures of proteins and drug-like molecules. By making these computations more efficient, Genesis and NVIDIA aim to improve the overall performance of the company’s AI models, expediting the identification of promising drug candidates and enhancing molecular design capabilities."